# DayTwo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/daytwo

- Industry: Healthcare IT
- Headquarters: Brentwood, US
- Website: www.daytwo.com
- Total disclosed funding: $48M
- Latest round: Series B (Oct 3, 2019)
- Investors on record: 8

## About

Founded in 2015 and based in Tennessee, US, DayTwo, Inc., operates as a microbiome-based precision medicine company that offers health monitoring and food recommending solutions for improving digestion, immunity, vitamin, production, and mental health. In July 2023, DayTwo, Inc., raised USD 85 million in venture funding from individual investors. As of 2023, the company is led by its CEO, Aamir Rehman.

DayTwo provides food-as-medicine solutions and gut microbiome profiling solutions used to predict blood sugar response to foods, which can be accessed by patients via their artificial intelligence-based platform and mobile application, helping them to lower A1C levels, weight loss, reduced medication usage, increased energy levels, better sleep, and reduced stress.

The company also provides personalized nutrition kits, which utilized stool samples to provide customized dietary recommendations for diabetic patients, along with microbiome analysis, precision nutrition, glucose and other vitals tracking, lifestyle coaching, medication management, and many more diabetic solutions.

The company generates revenue by providing organizations with employer benefit programs and selected health plans.

The company plans to use the July 2023 funding to continue supporting its current clients.

## Funding rounds

- Series B, Oct 3, 2019, $5M — Cathay Capital, Samsung NEXT Ventures, Longliv Ventures
- Series B, Jun 26, 2019, $31M — Seventure Partners, Johnson & Johnson Innovation, Cathay Capital, Samsung NEXT Ventures, aMoon, Longliv Ventures, Galil Ofek Ventures
- Series A, Jun 27, 2017, $12M — Seventure Partners, Johnson & Johnson Innovation, Mayo Clinic

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- Mayo Clinic — Series A
- Cathay Capital — Series B
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series B
- Longliv Ventures — Series B
- Galil Ofek Ventures — Series B